Jignesh Patel, 46, and Rahil Patel, 42, walked out of the courtroom on Tuesday, not as free men, but as convicted fraudsters facing six years behind bars. The judge, Justin Cole, handed down the sentences after the pair failed to deny their guilt in a scheme that siphoned £1.3 million from the NHS between 2014 and 2017. It wasn't a messy, small-time theft. It was a calculated, industrial-scale heist disguised as pharmacy operations.
The mechanics were cold and precise. Jignesh, director of Wise Pharmacy in Edmonton and Actipharm Limited, his wholesale arm, didn't just fill scripts. He invented them. Investigators counted 1,639 fraudulent prescriptions linked to 440 patients who never saw a doctor for those specific drugs. The targets were high-value: Sprycel for leukaemia, Noxafil for fungal infections in chemo patients. These weren't paracetamol. These were life-saving agents diverted to the black market.
The money trail led north of London and then out of the country. Actipharm sold the stolen meds to two EU wholesalers, raking in roughly £780,000 while the UK was still in the single market. The trail went cold in the EU, but the digital footprint didn't. Text messages between the brothers—discussed in hushed tones at trial—revealed the logistics of obtaining false prescriptions. They thought they were clever. They weren't.
The damage went beyond the ledger. Prosecutor William Davis KC told the jury this was a direct attack on the taxpayer. The fraud touched four NHS areas: Barnet, Enfield, Newham, and Tower Hamlets. It involved 24 GPs whose names were misused and hundreds of patients whose identities were hijacked. No one died from a lack of medicine, but the system that should have protected them was bled dry by two men who saw a loophole as a business plan.
Now, the cleanup begins. Police raided Jignesh’s properties in December 2017 and grabbed £190,000 in cash. That’s a start. The NHS Counter Fraud Authority is now turning to the Proceeds of Crime Act 2002 to claw back the rest. For the Patels, the next six years will be served in custody, with the remaining time on licence. The NHS, strained and underfunded, gets its money back. Or at least, it tries. The EU buyers? They’re out of reach. The lessons? Expensive.